Legal4 Jun 2026, 03:40 pm
AstraZeneca Pharma India faces ₹9.24 Cr tax appeal order
AI Summary
AstraZeneca Pharma India Ltd has received an appeal order from the Deputy Commissioner of State Tax (Appeal) concerning the financial year 2018-19. The order upholds adjustments made by the Assistant Commissioner of State Tax Investigation related to supplies under the Patient Access Program. The company plans to challenge this order before the GST Appellate Tribunal (GSTAT). The disputed amount is approximately ₹9.24 crores, excluding interest and penalty, with the overall financial implication not yet determinable.
Key Highlights
- Received appeal order from Deputy Commissioner of State Tax (Appeal).
- Dispute pertains to financial year 2018-19 and Patient Access Program supplies.
- Company to challenge the order before the GST Appellate Tribunal (GSTAT).
- Quantum of claims is approximately ₹9.24 crores, excluding interest and penalty.
- Expected financial implications are currently undetermined.
Price Impact
More from ASTRAZEN